BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16357454)

  • 1. Pathological complete response in advanced gastrointestinal stromal tumor after imatinib therapy.
    Melichar B; Voboril Z; Nozicka J; Ryska A; Urminská H; Vanecek T; Michal M
    Intern Med; 2005 Nov; 44(11):1163-8. PubMed ID: 16357454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
    Zhu J; Yang Y; Zhou L; Jiang M; Hou M
    BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy.
    Jamali FR; Darwiche SS; El-Kinge N; Tawil A; Soweid AM
    Oncologist; 2007 Apr; 12(4):438-42. PubMed ID: 17470686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete remission of recurrent gastrointestinal stromal tumors after treatment with imatinib: report of a case.
    Kobayashi M; Okamoto K; Nakatani H; Okabayashi T; Namikawa T; Ichikawa K; Kitagawa H; Araki K
    Surg Today; 2006; 36(8):727-32. PubMed ID: 16865518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A resected case of postoperative liver metastasis of a gastrointestinal stromal tumor showing complete response after imatinib treatment].
    Yamamura M; Hirai T; Higashida M; Kubota H; Murakami H; Kawabe Y; Ikeda M; Hirabayashi Y; Okawaki M; Hironaka K; Oka Y; Okumura H; Akiyama T; Matsumoto H; Urakami A; Yamashita K; Yamaguchi Y; Tsunoda T
    Gan To Kagaku Ryoho; 2008 Nov; 35(11):1945-9. PubMed ID: 19011349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model.
    Gold JS; Dematteo RP
    Ann Surg; 2006 Aug; 244(2):176-84. PubMed ID: 16858179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
    Nishida T; Omori T; Ueshima S
    Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors.
    De Giorgi U; Aliberti C; Benea G; Conti M; Marangolo M
    Clin Cancer Res; 2005 Sep; 11(17):6171-6. PubMed ID: 16144917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.
    Bauer S; Hartmann JT; de Wit M; Lang H; Grabellus F; Antoch G; Niebel W; Erhard J; Ebeling P; Zeth M; Taeger G; Seeber S; Flasshove M; Schütte J
    Int J Cancer; 2005 Nov; 117(2):316-25. PubMed ID: 15900603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successful resection of locally advanced gastrointestinal stromal tumor of the ampulla of Vater after treatment with imatinib].
    Park JE; Dong SH; Cho KH; Jang JY; Kim HJ; Kim BH; Chang YW; Chang R
    Korean J Gastroenterol; 2010 Jul; 56(1):39-44. PubMed ID: 20695129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST).
    Rutkowski P; Nyckowski P; Grzesiakowska U; Nowecki ZI; Nasierowska-Guttmejer A; Pienkowski A; Dudek K; Krawczyk M; Ruka W
    Neoplasma; 2003; 50(6):438-42. PubMed ID: 14689066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant stromal tumor of the stomach with giant cystic liver metastases prior to treatment with imatinib mesylate.
    Colović R; Micev M; Matić S; Colović N; Grubor N; Atkinson HD
    Vojnosanit Pregl; 2013 Feb; 70(2):225-8. PubMed ID: 23607193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene.
    Yamaguchi M; Matsumoto T; Tate G; Higuchi T
    J Gastroenterol; 2004 Sep; 39(9):904-5. PubMed ID: 15565413
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful resection of an advanced duodenal gastrointestinal stromal tumor after down-staging with imatinib: report of a case.
    Ludvigsen L; Toxvaerd A; Mahdi B; Krarup-Hansen A; Bergenfeldt M
    Surg Today; 2007; 37(12):1105-9. PubMed ID: 18030576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case.
    Utsunomiya T; Okamoto M; Yano S; Kameyama T; Matsuyama A; Kuma S; Yamamoto M; Fujiwara M; Ishida T
    Surg Today; 2008; 38(1):65-7. PubMed ID: 18085368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib.
    Schindler CG; Armbrust T; Gunawan B; Langer C; Füzesi L; Ramadori G
    Z Gastroenterol; 2005 Mar; 43(3):267-73. PubMed ID: 15765299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials.
    Eisenberg BL
    Clin Colorectal Cancer; 2006 Nov; 6 Suppl 1():S24-9. PubMed ID: 17101065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.
    Shen C; Chen H; Yin Y; Chen J; Zhang B; Chen Z; Chen J
    Clinics (Sao Paulo); 2014 Nov; 69(11):758-62. PubMed ID: 25518034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib for imatinib-resistant GIST.
    Joensuu H
    Lancet; 2006 Oct; 368(9544):1303-4. PubMed ID: 17046443
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.